Drug evaluation: TG-1042, an adenovirus-mediated IFNgamma gene delivery for the intratumoral therapy of primary cutaneous lymphomas.
Transgene SA is developing TG-1042, a replication-deficient adenovirus type 5 that carries the IFNgamma gene, for the potential treatment of cutaneous T-cell and B-cell lymphoma (CTCL and CBCL, respectively). A phase I/II clinical trial in CTCL and CBCL was recently completed, and in November 2006 Transgene initiated a phase II clinical trial in CBCL.
Urosevic
Mirjana
M
Address UniversitätsSpital Zürich, Dermatologische Klinik, Gloriastrasse 31, 8091 Zürich Switzerland. mirjana.urosevic@usz.ch
D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D015316:Genetic Therapy; D006801:Humans; D007371:Interferon-gamma / Q000138:chemical synthesis / Q000235:genetics* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy* / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000970:Antineoplastic Agents; D007371:Interferon-gamma